Trial Profile

A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buparlisib (Primary) ; Trametinib (Primary)
Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Pharmacogenomic
Sponsors Novartis

Most Recent Events

17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
12 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
12 Nov 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com